
Personalized Cancer Vaccine Proves Promising in a Phase 1 Trial at Mount Sinai
New York, NY, March 21, 2025 (GLOBE NEWSWIRE) -- Key Findings: This study demonstrates that tailored vaccines targeting patient-specific neoantigens (proteins that can trigger an immune response against cancer) can generate a potent immune response, with …